Video

Dr. Van Tine Discusses Potential Novel Treatment Modalities for Sarcoma

Brian A. Van Tine, MD, PhD, assistant professor, Washington University School of Medicine in St. Louis, discusses some potential novel treatment modalities for the treatment of sarcoma.

Brian A. Van Tine, MD, PhD, assistant professor, Washington University School of Medicine in St. Louis, discusses some potential novel treatment modalities for the treatment of sarcoma.

At the 2014 ASCO Annual Meeting, Dr. Sujana Movva presented data on predictive biomarker profiling of over 1900 sarcomas. Van Tine says the data that resulted from this analysis will help shape future clinical trial targets.

The analysis showed that sarcoma may be a disease resulting in the loss of PTEN, which helps researchers get an idea of how to direct future clinical trials. The analysis also showed that SPARC was overexpressed in the majority of the sarcomas that were analyzed, Van Tine says.

These findings are exciting, Van Tine says, because this gives researchers an idea of some commonalities among the disease type.

Related Videos
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic